Q-omics provides the consensus-scored NUTM2E profile across patient tissues and cancer cell-line models. NUTM2E expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, NUTM2E is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, NUTM2E RNA expression shows 4,259 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight TGCT, LIHC, and GBM as cancer lineages where NUTM2E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2E survival associations across molecular data types. NUTM2E RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2E RNA expression–survival associations across cancer types. High NUTM2E expression shows unfavorable associations in TGCT, ESCA and SKCM, but favorable associations in KIRP, STAD and LUAD. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify TGCT as the clearest survival context for NUTM2E RNA expression.
This table summarizes NUTM2E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2E shows lower tumor expression in KIRC and LUAD and higher tumor expression in LIHC. The LIHC box plot shows higher NUTM2E RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p = .028).
This table shows molecular features associated with NUTM2E in patient tissues and cancer cell lines. In patient samples, NUTM2E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH.
